



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARG5

Last Trade: 0.16

Trade Time: 4:00 PM ET
Dec 15, 2017

Change: 0.01 
(+5.270%)

Day Range 0.15 - 0.16

52-Week Range 0.13 - 5.68


Volume 2,430,370

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 28, 2017

[Argos Provides Financial Update](#)

Nov 11, 2017

[Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting](#)

Nov 9, 2017

[Argos Reports Third Quarter 2017 Financial Results and Operational Highlights](#)

Nov 6, 2017

[Argos Announces Receipt of Milestone Payment from Lummy \(Hong Kong\) Co. Ltd.](#)

Nov 6, 2017

[Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017](#)

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Jul 6, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)